330 results
8-K
EX-3.2
IMGN
Immunogen, Inc.
12 Feb 24
Termination of a Material Definitive Agreement
7:52am
of the shareholders, a majority of votes entitled to be cast on a matter shall constitute a quorum, except when a larger quorum is required by law, by the Articles … of Organization or by these Bylaws. If there is less than a quorum at a meeting, a majority of the shares represented may vote to adjourn indefinitely
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
is necessary to hold a valid Special Meeting. The holders of a majority in interest of the issued and outstanding shares of Company Common Stock … .
Approval of the Compensation Proposal, on a non-binding, advisory basis, requires, assuming a quorum is present, the affirmative vote of a majority
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
. The holders of a majority in interest of the issued and outstanding shares of Company Common Stock entitled to vote at the Special Meeting, present … vote of a majority of the shares of Company Common Stock properly cast at the Special Meeting on the proposal. The approval of the Compensation
DEFA14A
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:08pm
to the satisfaction of customary closing conditions and regulatory approvals, including the tender by shareholders of a majority of ImmunoGen’s outstanding shares
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
) a Restricted Party or (ii) majority-owned or controlled by one or more Restricted Parties.
(b) Except as would not reasonably be expected to have … and is not the continuing or surviving corporation or entity resulting from such consolidation or merger or (ii) transfers all or a majority of its properties
8-K
EX-2.1
p37nkumc9afi o49zt7
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-3.1
anohzd bgelq3
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
424B5
5ev1m7wm 8zur
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
vffholmyl832zw2y6h
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
s9d0fo6zhxcmf8o43
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
EX-10.1
zcs58f1w
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-3.1
fxcz3x0
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99.1
epdm2rx
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
8-K
EX-10.1
vy7n cyg2
17 Jun 22
Departure of Directors or Certain Officers
5:07pm